Solid Biosciences (SLDB) Receivables (2021)

Solid Biosciences (SLDB) reported Receivables of $220000.0 for Q4 2021.

Solid Biosciences (SLDB) Receivables (2021) Analysis & Trends

Solid Biosciences (SLDB) has 1 years of Receivables data on file, last reported at $220000.0 in Q4 2021.

For the quarter ending Q4 2021, Receivables changed N/A year-over-year to $220000.0; the trailing twelve-month figure through Dec 2021 stood at $220000.0 (changed N/A YoY), and the FY2021 full-year result was $220000.0, changed N/A from the prior year.
Receivables was little changed at $220000.0 in Q4 2021.
In the past five years, Receivables ranged from a high of $220000.0 in Q4 2021 to a low of $220000.0 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Solid Biosciences	529.40 Mn	529.40 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	220,000.00